Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the UK, however, the publication of J. Y. Dent's (who later went on to treat Burroughs) 1934 paper "Apomorphine in the treatment of Anxiety States" laid out the main method by which apomorphine would be used to treat alcoholism in Britain. His method in that paper is clearly influenced by the then-novel idea of aversion:He is given his favourite drink, and his favourite brand of that drink ... He takes it stronger than is usual to him ... The small dose of apomorphine, one-twentieth of a grain [3.24 mg], is now given subcutaneously into his thigh, and he is told that he will be sick in a quarter of an hour. A glass of whisky and water and a bottle of whisky are left by his bedside. At six o'clock (four hours later) he is again visited and the same treatment is again administered ... The nurse is told in confidence that if he does not drink, one-fortieth [1.62 mg] of a grain of apomorphine should be injected during the night at nine o'clock, one o'clock, and five o'clock, but that if he drinks the injection should be given soon after the drink and may be increased to two hourly intervals. In the morning at about ten he is again given one or two glasses of whisky and water ... and again one-twentieth of a grain [3.24 mg] of apomorphine is injected ... The next day he is allowed to eat what he likes, he may drink as much tea as he likes ...
In May 2025, the government announced this decision, citing a worsening global economic outlook and the need to reallocate the remaining 157-billion-baht budget to more urgent stimulus measures, such as infrastructure development and tourism promotion. Paetongtarn has publicly insisted that the postponement is not a cancellation and that the government remains committed to fulfilling its promise once economic conditions improve. The policy has been a focal point of her premiership, drawing both support for its potential to aid households and strong criticism from economists for its high cost and debated effectiveness as a stimulus tool.
Benign acute childhood myositis (BACM) is a syndrome characterized by muscle weakness and pain in the lower limbs that develop in children after a recent viral illness. It is transient with a spontaneous clinical resolution within 1 week.
GamePro stated that "Gearbox has done one hell of a job in creating not just an add-on for Half-Life, but a continuation of a masterpiece", praising both level design and story elements, but noted that it was a little too short. However, some critics dissented on the idea that Opposing Force was as influential as other reviewers made out. PC Zone stated that "the taste left in the mouth is a bitter one", noting that "Opposing Force is a few excellent ideas strung together by pedestrian Half-Life padding", but concluded that "it was still a good weekend's worth of entertainment". Eurogamer stated that Opposing Force still had similar problems to other expansion packs, commenting that "X amount of new content has been created and it is going to be cut into the old content in a linear way to make it look like an all new game", but noted that "fortunately though the new stuff in Opposing Force... is pretty damn good". Although praising the level design as the game's strongest point, the reviewer felt that "towards the end of the game... they were running out of development time". Reviewing for IGN, Vincent Lopez stated that the game "does a fantastic job of making you remember exactly why you enjoyed the original so much", but criticized this as the biggest drawback, commenting that "you may find yourself wishing for a more original experience", but concluded that "for good, and bad: it's good to be back".
Sources: en.wikipedia.org
== Adverse effects == Although generally well tolerated, the most common adverse reactions associated with ceftriaxone are changes in white blood cell counts, local reactions at site of administration, rash, and diarrhea. Incidence of adverse effects greater than 1%:
=== As a fungicide and herbicide === Copper sulfate has been used for control of algae in lakes and related fresh waters subject to eutrophication. It "remains the most effective algicidal treatment". Bordeaux mixture, a suspension of copper(II) sulfate (CuSO4) and calcium hydroxide (Ca(OH)2), is used to control fungus on grapes, melons, and other berries. It is produced by mixing a water solution of copper sulfate and a suspension of slaked lime. A dilute solution of copper sulfate is used to treat aquarium fishes for parasitic infections, and is also used to remove snails from aquariums and zebra mussels from water pipes. Copper ions are highly toxic to fish. Most species of algae can be controlled with very low concentrations of copper sulfate.
After a few attempts, he produced a model with physically plausible hydrogen bonds. Pauling then worked with Corey and Branson to confirm his model before publication. In 1954, Pauling was awarded his first Nobel Prize "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances" (such as proteins), prominently including the structure of the α-helix.
In 2011, Talarico joined Teach For America, teaching sixth-grade English language arts at Rhodes Middle School on the west side of San Antonio. After two years of teaching, he became Central Texas executive director for Reasoning Mind, a nonprofit that implements computer-based math lessons in classrooms.
== Mechanisms == There are two known mechanisms for RNA helicase unwinding: canonical duplex unwinding and unwinding by local strand separation. During canonical duplex unwinding, the helicase first binds to the single stranded region, then uses ATP hydrolysis as a power stroke in order to translocate the helicase across the strand. As the helicase slides down one strand, it is dissociating the two strands and removing the complementary. Finally, the helicase is removed.
Sources: en.wikipedia.org
== Taxonomy == Amanita verna was first mentioned in the scientific literature by French mycologist Jean Bulliard in 1780 as form vernus of Agaricus bulbosus. Bulliard warned that it could be easily confused with the edible field mushroom (Agaricus campestris), and that remedies for those who had eaten it included putting vitriolic ether in wine or crushed garlic in milk. The species name verna is derived from the Latin word for "spring". Three years later, Jean-Baptiste Lamarck gave it distinct species status in his Encyclopédie Méthodique, Botanique. A. verna is a close relative of A. phalloides (the death cap); both species belong to the Amanita subfamily Phalloideae.
To reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy in men Androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss in women as well as high testosterone levels due to polycystic ovary syndrome (PCOS) in women, at 25 to 50 mg/day generally in combination with a birth control pill Feminizing hormone therapy for transgender women usually at 50 mg/day in combination with an estrogen. Peripheral precocious puberty in boys at 12.5 to 100 mg/day in combination with an aromatase inhibitor like anastrozole, especially for familial male-limited precocious puberty (testotoxicosis) Overly long-lasting erections in men at 50 mg per week to 50 mg every other day The medication has been suggested for but has uncertain effectiveness in the following indication:
Trading with the Enemy Act of 1917 Foreign Assistance Act of 1961 International Emergency Economic Powers Act of 1977 Export Administration Act of 1979 Several laws specifically prohibit trade with certain countries:
UPMC Magee-Womens Hospital is a UPMC specialty hospital that serves as its primary facility for women's health. Opened mainly for women on January 19, 1911, it has offered some services for men since the 1960s. The hospital is located in the Oakland neighborhood of Pittsburgh near UPMC Presbyterian, a location it has been at since its fourth year in 1915. The hospital merged with UPMC in 1999. It currently is equipped with 360 beds, an emergency room and ambulatory facilities on four floors which allows it to offer all possible services under one roof including family medicine physicians, gastroenterologists, dermatologists, rheumatologists, pulmonary specialists, orthopedists, urologists and neurologists. Magee-Womens has a staff of 2,500, of which 1,500 are medically licensed. It also operates a satellite hospital in the city's northern suburbs as part of the UPMC Passavant facility as well as 9 metro area imaging clinics. In 2011 the hospital undertook an expansion of its main facility which was completed in June 2012. The expansion added six floors, increased the number of beds from 318 to 360 (including 14 additional intensive care rooms), and expanded the surgical and ambulatory facilities. 10,000 births are performed at Magee each year, which accounts for 45 percent of all births in Allegheny County. The hospital is built on the grounds of the home of legendary Pittsburgh political boss Christopher Magee and named in honor of his mother, Elizabeth Steel Magee.
== History == Orexigen Therapeutics submitted a New Drug Application (NDA) for the combination to the FDA in March 2010. Having paid a fee under the Prescription Drug User Fee Act, Orexigen was given a deadline for the FDA to approve or reject the drug of January 2011. In December 2010, an FDA Advisory Committee voted 13–7 to approve Contrave and 11–8 to conduct a post-marketing cardiovascular outcomes study. Subsequently, on 2 February 2011, the FDA rejected the drug, and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed before approval could be considered. It was ultimately approved in the United States in 2014. In December 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency endorsed the combination for licensure as an obesity medication when used alongside diet and exercise. Authorization was granted in March 2015. A review of Mysimba was completed by the CHMP in March 2025. In May 2015, Orexigen prematurely ended the trial that was intended to test whether naltrexone/bupropion increased the risk of major adverse cardiovascular events in obese patients with cardiovascular disease because an independent panel of experts said that the drug maker "inappropriately" compromised the trial by prematurely releasing interim data. The early data release reported a reduction in heart attacks, but that advantage was no longer observed when a more complete view of the data was analyzed.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.